长链非编码RNA在卵巢癌中的研究进展

长链非编码RNA (lncRNA)是指长度超过200个核苷酸、具有调控基因表达作用的非编码RNA,近年来,因其具有复杂的生物学功能而引起了研究者的广泛关注.目前研究证实,lncRNA与多种肿瘤的发生发展有着密切的关系,可能参与促进或抑制肿瘤的生长和与肿瘤的转移有关.在卵巢癌中,某些lncRNA也被证实可能参与其致病过程.     

长链非编码RNA LOXL1-AS1在人类恶性肿瘤中的作用及其分子调控机制

长链非编码RNA(lncRNA)广泛参与生物体的各种生理与病理过程。lncRNA作为肿瘤致癌因子或抑癌因子参与恶性肿瘤的多种生物过程，与恶性肿瘤的发生、发展密切相关。赖氨酰氧化酶样蛋白1-反义RNA1(LOXL1-AS1)是近年来发现的一种lncRNA,其在多种恶性肿瘤中表达上调，并与肿瘤大小、TNM分期、淋巴结转移、患者预后等病理特征相关。LOXL1-AS1通过与多种微小RNA竞争性结合，调节下游靶基因的表达及调控相关信号通路发挥促癌作用。该文通过总结LOXL1-AS1参与多种人类恶性肿瘤的生物学过程，不同的分子调控机制影响肿瘤细胞增殖、转移、侵袭和凋亡等恶性生物学行为，探讨潜在的临床意义和应用前景，以期为恶性肿瘤的临床诊断、治疗和筛选预后标志物提供理论基础和参考依据。     

长链非编码RNA通过ceRNA在乳腺癌中的调控机制

长链非编码RNA(long non-coding RNA,lncRNA)是一种长度大于200 nt的不具有编码蛋白质功能的RNA。lncRNA在多种肿瘤中存在差异性表达,通过转录调控、转录后调控等方式影响肿瘤的增殖、侵袭、转移、耐药等。多项研究表明,lncRNA可通过竞争性内源性RNA(competing endogenous RNA,ceRNA)机制与miRNA相互作用,并影响其它RNA、蛋白的表达,影响疾病进程;提示lncRNA可能是一种肿瘤标志物和潜在的治疗靶点。该文现就lncRNA通过ceRNA调控乳腺癌的研究进展进行综述。     

肺腺癌转移相关转录因子1在口腔鳞状细胞癌组织中的表达及临床意义

目的分析口腔鳞状细胞癌组织中长链非编码RNA(lncRNA)肺腺癌转移相关转录因子1(MALAT1)的表达及其临床意义。方法收集口腔鳞癌组织标本81例和正常口腔黏膜组织20例,分别设为口腔鳞癌组和健康对照组。采用RT-PCR方法检测2组组织中lncRNA MALAT1表达情况,统计分析lncRNA MALAT1表达与病理资料特征的关系,Kaplan-Meier分析lncRNA MALAT1表达和生存预后间的关系。结果与健康对照组相比,lncRNA MALAT1在口腔鳞癌组中表达明显增高,差异有统计学意义(P 0. 05);口腔癌组织中lncRNA MALAT1的相对表达量在不同肿瘤分期、肿瘤分化程度和有无颈部淋巴结转移间比较,差异均有统计学意义(P 0. 05);而在不同年龄、性别、肿瘤大小及肿瘤类型间比较,差异均无统计学意义(P 0. 05); lncRNA MALAT1高表达组和低表达组患者的3年总体生存率(OS)分别为45. 9%(17/37)、65. 9%(29/44),Kaplan-Meier生存分析(log-rank检验)表明MALAT1高表达组患者3年OS显著低于MALAT1低表达组患者,差异有统计学意义(P 0. 05)。结论口腔鳞癌组织中lncRNA MALAT1表达增高,其表达水平与口腔鳞癌患者的不良预后有关,在口腔鳞癌组织中检测其表达可能有助于肿瘤的诊断及作为药物治疗的靶点。     

长链非编码RNA调控肿瘤细胞凋亡的研究进展

长链非编码RNA(long non-coding RNA,lncRNA)是一类长度>200个核苷酸、通常不编码蛋白质的RNA。近年研究表明,lncRNA在肿瘤的的发展过程中发挥抑癌或促癌作用,参与细胞增殖、凋亡等过程。本综述简要介绍lncRNA的生物学功能及其调控细胞凋亡的研究进展。     

长链非编码RNA低表达或表达缺失与恶性肿瘤发生的研究进展

长链非编码RNA(lncRNA)是指长度超过200个核苷酸的非编码RNA,其通过与DNA、RNA和蛋白质等分子相互作用,从表观遗传学、转录水平以及转录后水平等3个层面发挥重要调控作用.近年研究表明,lncRNAs在许多肿瘤的发生、发展过程中发挥着促癌或抑癌作用,部分lncRNAs因其特殊的生物学特性有希望成为新型肿瘤标记物和肿瘤治疗的新靶点.本文总结了近年来在肿瘤中低表达或呈表达缺失的lncRNAs,探讨其与肿瘤发生的相关机制,评价其在肿瘤诊断和治疗方面的临床应用前景.     

长链非编码RNA与口腔癌研究进展

口腔癌(oral cancer)是口腔外科常见的恶性肿瘤,易发生转移且预后不容乐观,长链非编码RNA(Long non-coding RNA,lncRNA)是一类内源性的长度大于200个核苷酸、缺少特异完整的开放阅读框,不具有蛋白质编码功能的转录本,最初认为并没有生物学功能,但随着生物学技术的发展,发现其能够在表观遗传水平、转录水平和转录后水平等多个层面上调控基因的表达,从而影响机体生长、发育、衰老和死亡等重要的生命活动以及疾病的发生和发展。近年来的研究显示口腔癌的发生、发展、侵袭、转移和预后与lncRNA的表达水平密切相关。因此本文对lncRNA在口腔癌中的研究进展进行论述,并探讨lncRNA与口腔癌发生、发展之间的关系,旨在进一步阐述lncRNA与OSCC的关系并为寻找口腔癌肿瘤标志物提供新的方向,为口腔癌患者提供新的治疗策略。     

TP73-AS1在肿瘤中的表达及调控作用

<正>随着高通量测序技术的发展,成千上万种长链非编码RNA(long non-coding RNA,lncRNA)进入人们的视野。lncRNA是一类长度超过200个核苷酸并缺少开放阅读框的不具备蛋白质编码功能的RNA~([1-2])。研究发现lncRNA参与诸多生物学进程的关键步骤,包括染色质重塑、基因转录、转录后调节和蛋白质翻译等~([3-5])。LncRNA机制的不断被阐明,也为肿瘤的研究提供了新的可能。LncRNA在多种肿瘤的增殖、迁移侵袭和抗凋亡     

lncRNA-CCAT1与消化道肿瘤关系的研究进展

结肠癌相关转录因子1(CCAT1)是结直肠癌组织中新近发现的一种异常高表达的长链非编码RNA(lncRNA),具有促进肿瘤细胞增殖及侵袭转移等作用。CCAT1通过内源竞争等机制与微小RNA(miRNA)或蛋白相互作用参与调控机体的诸多生理病理过程,尤其是消化道肿瘤的形成与发展,它有望成为有价值的肿瘤标志物和治疗靶点。     

长链非编码RNA调控巨噬细胞功能的作用机制研究进展

长链非编码RNA(lncRNA)是一类本身不编码蛋白、转录本长度超过200 bp的RNA.lncRNA最初被认为是RNA聚合酶Ⅱ转录的副产物,是一种"噪音",不具有生物学功能.但近年研究证实,lncRNA参与X染色体沉默、染色体修饰和基因组修饰、转录激活、转录干扰、核内运输等过程,其调控作用被越来越多研究者关注.多个研...     

长链非编码MALAT-1 调控miR-205 的表达影响非小细胞肺癌细胞的生长和迁移

目的:探讨在非小细胞肺癌中,LncRNA MALAT-1 与miR-205 的相互关系,以及影响肺癌细胞生物学行为的机制。方法:qPCR 检测不同非小细胞肺癌中LncRNA MALAT-1 的表达情况;双荧光素酶报告基因检测MALAT-1 与miR-205的相互作用;Transwell 侵袭实验和划痕实验检测抑制MALAT-1 后肺癌细胞侵袭能力的变化,以及抑制miR-205 的表达后肺癌细胞迁移和侵袭能力的恢复情况;裸鼠皮下成瘤检测抑制LncRNA MALAT-1 后肺癌细胞体外成瘤体积和质量变化。结果:与其他肺癌细胞株相比,A549 细胞中MALAT-1 表达最高,miR-205 的表达水平最低;双荧光素酶实验证实MALAT-1 能与miR-205 的3忆UTR 特异性结合,可以调控miR-205 的表达与活性;抑制MALAT-1 的表达后可以降低肺癌细胞的迁移和侵袭能力;抑制miR-205 的表达水平过后,肺癌细胞的迁移和侵袭能力相对增强;抑制MALAT-1 的表达后,荷瘤小鼠的肿瘤体积和重量都明显减小。结论:MALAT-1 可以调控miR-205 的表达影响肺癌细胞A549 的侵袭和迁移能力。     

Overexpression of long non-coding RNA CCAT1 is a novel biomarker of poor prognosis in patients with breast cancer

Introduction: Recent studies have demonstrated that lncRNA CCAT1 was increased in many types of cancers and was involved in various cellular processes related to carcinogenesis. However, the clinical significance and prognostic value of lncRNA CCAT1 in breast cancer (BC) haven’t been investigated. Methods: Expression levels of lncRNA CCAT1 in 92 pairs of BC cancer tissues and adjacent normal tissues were detected by quantitative real-time PCR. In order to determine its prognostic value, overall survival and progression-free survival were evaluated using the Kaplan-Meier method, and multivariate analysis was performed using the Cox proportional hazard analysis. Results: Expression levels of lncRNA CCAT1 in BC tissues were significantly higher than those in adjacent normal tissues. High expression of lncRNA CCAT1 was associated with differentiation grade, TNM stage, and lymph node metastases. Kaplan-Meier analysis with the log-rank test indicated that high expression of lncRNA CCAT1 had a decreased overall survival and progression-free survival. Multivariable analysis was further identified high expression of lncRNA CCAT1 as an independent prognosis factor for overall survival and progression-free survival. Conclusions: Our findings provided that the expression of lncRNA CCAT1 was up-regulated in BC and associated with overall survival as well as progression-free survival, suggesting that lncRNA CCAT1 could be a potential prognostic biomarker for BC progression.     

LncRNA CCAT1通过调控MYC蛋白的表达激活MAPK信号通路影响胃癌细胞的生物学行为

目的：探讨lncRNA CCAT1通过调控瘤细胞病毒癌基因（MYC）蛋白的表达激活MAPK信号通路影响胃癌细胞的生物学行为及机制。方法：qPCR检测lncRNA CCAT1在胃癌组织和不同胃癌细胞株中的表达情况;qPCR检测MYC在胃癌组织中的表达和lncRNA CCAT1的关系,双荧光素酶报告基因检测lncRNA CCAT1和MYC之间的相互作用;流式细胞术实验检测lncRNA CCAT1对胃癌细胞的凋亡行为和细胞周期的影响;划痕愈合试验和Transwell侵袭实验检测lncRNA CCAT1对胃癌细胞的迁移和侵袭行为的变化情况;Western blot实验检测lncRNA CCAT1对MAPK通路相关蛋白表达情况的影响。结果：与正常胃组织相比,胃癌组织中lncRNA CCAT1的表达水平相对上调,与其他细胞株相比,HCG-27细胞中lncRNA CCAT1表达最高;MYC表达与相对lncRNA CCAT1的表达呈负相关关系;双荧光素酶实验证实lncRNA CCAT1能与MYC的3′UTR特异性结合,可以调控MYC的表达与活性;抑制lncRNA CCAT1的表达可以诱导G0/G1期的细胞周期停滞并促进细胞凋亡;抑制lncRNA CCAT1的表达后可以抑制胃癌细胞的迁移和侵袭能力;抑制lncRNA CCAT1后下游MAPK通路蛋白表达水平相应下调。结论：LncRNA CCAT1通过调控MYC蛋白表达激活MAPK信号通路影响胃癌细胞的生物学行为。     

Increased expression of the lncRNA PVT1 promotes tumorigenesis in non-small cell lung cancer

Introduction: Non-small cell lung cancer (NSCLC) is the major cause of cancer death worldwide. Increasing evidence shows that long non coding RNAs (lncRNAs) are widely involved in the development and progression of NSCLC. lncRNA PVT1 in several cancers has been studied, its role in lung cancer remains unknown. Our studies were designed to investigate the expression, biological role and clinical significance of PVT1 in lung cancer. Methods: lncRNA PVT1 expression in 82 NSCLC tissues and 3 lung cancer cell lines was measured by quantitative Real-time PCR (qRT-PCR). Its association with overall survival of patients was analyzed by statistical analysis. RNA interference (RNAi) approaches were used to investigate the biological functions of PVT1. The effect of PVT1 on proliferation was evaluated by MTT, cell migration and invasion ability was evaluated by cell migration and invasion assays. Results: lncRNA PVT1 expression was significantly upregulated in NSCLC tissues and lung cancer cells when compared with corresponding adjacent normal tissues and normal bronchial epithelial cells. Increased PVT1 expression was significantly correlated with histological grade and lymph node metastasis. In addition, NSCLC patients with PVT1 higher expression have shown significantly poorer overall survival than those with lower PVT1 expression. And PVT1 expression was an independent prognostic marker of overall survival in a multivariate analysis. In vitro assays our results indicated that knockdown of PVT1 inhibited cell proliferation, migration, and invasion. Conclusions: Our data indicated that lncRNA PVT1 is significantly upregulated in NSCLC tissues and may represent a new biomarker and a potential therapeutic target for NSCLC intervention.     

Decreased expression of lncRNA loc285194 as an independent prognostic marker in cancer: A systematic review and meta-analysis

BackgroundSeveral studies have indicated that lncRNA loc285194 is aberrantly expressed in many types of cancer. This meta-analysis was performed to elucidate the potential role of lncRNA loc285194 as a prognostic marker in malignant tumors.MethodsAn electronic search of PubMed, Medline, Embase, and Web of Science was performed to identify all eligible papers related to the prognostic impact of lncRNA loc285194 expression in cancer. Hazard ratios (HR) and 95% confidence intervals (CI) were extracted from the included studies to explore the association between lncRNA loc285194 expression and patient overall and disease-free survival (OS & DFS). The odds ratios (ORs) were also calculated to assess the association between lncRNA loc285194 expression and clinicopathological parameters.ResultsA total of 14 eligible articles with 1215 patients were included in this meta-analysis. Meta-results revealed that low expression of lncRNA loc285194 was significantly correlated with poorer overall survival (OS; HR = 2.34; 95% CI, 1.78–3.06; P < 0.001) and disease-free survival (DFS; HR = 2.66; 95% CI, 1.95–3.64; P = 0.001) rates in cancer patients. Low lncRNA loc285194 expression was also found to be significantly associated with lymph node metastasis (LNM; OR = 2.17; 95% CI, 1.23–3.83; P = 0.007), and distant metastasis (DM; OR = 2.49; 95% CI, 1.26–4.91; P = 0.009).ConclusionsThis study demonstrated that decreased level of lncRNA loc285194 was associated with poor clinical outcomes for patients with different types of cancer, supporting a promising potential biomarker for prognosis and metastasis in human cancers.     

Prognostic value of long non-coding RNA ATB in digestive system cancers: A meta-analysis

BackgroundThe present meta-analysis has evaluated the association between lncRNA ATB, prognosis and clinicopathological parameters in patients with digestive cancers.MethodsEligible studies were gathered from Web of Science, PubMed, Embase, Cochrane Library, WanFang databases and China National Knowledge Infrastructure (up to October 15, 2019). Hazard ratios (HRs) and 95 % confidence intervals (CIs) were calculated to estimate the prognosis and clinicopathological parameters of lncRNA ATB in patients with digestive cancers.ResultWe divided this study into two groups, pancreatic cancer (PC, downregulation) and non-pancreatic cancer (non-PC, upregulation). In the non-PC group, high expression levels of lncRNA ATB were significantly related to poor OS (pooled HR = 2.19, 95 % CI 1.68–2.85, P＜0.00001). In contrast, increased levels of lncRNA ATB in pancreatic cancer tissue were favorable factors in OS (HR = 0.47, 95 % CI 0.32−0.69, P = 0.0001). The pooled data suggested that high expression levels of lncRNA ATB predicted a poor DFS in CRC and a poor RFS in HCC. Increased expression of lncRNA ATB was correlated with negative lymph node metastasis and TNM stage in the non-PC group. In contrast, lncRNA ATB were favorable factors for LNM and TNM stages in pancreatic cancer.ConclusionLncRNA ATBs, whether cancer promoters or suppressors, were potential biomarkers and therapeutic targets for digestive system cancers.